Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Revenue of Pulse Biosciences, Inc. (PLSE)
Revenue in 2023 (TTM): $
According to Pulse Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pulse Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,207,000 | $-42,367,000 | $-42,210,000 | $-42,210,000 |
| 2022 | $700 K | $-11,244,000 | $-56,702,000 | $-58,505,000 | $-58,953,000 |
| 2021 | $1.42 M | $-550,000 | $-61,868,000 | $-63,660,000 | $-63,160,000 |
| 2020 | $ | $-665,000 | $-48,870,000 | $-49,851,000 | $-49,737,000 |
| 2019 | $ | $-666,000 | $-46,794,000 | $-46,971,000 | $-45,988,000 |
| 2018 | $ | $-665,000 | $-36,653,000 | $-37,545,000 | $-37,545,000 |
| 2017 | $ | $-665,000 | $-24,566,000 | $-25,567,000 | $-25,567,000 |
| 2016 | $ | $-665,000 | $-8,827,000 | $-9,518,000 | $-9,518,000 |
| 2015 | $ | $ | $-3,750,965 | $-4,467,949 | $-2,811,283 |
| 2014 | $ | $ | $-108,000 | $-514,286 | $-474,857 |